Fmr LLC Trims Stock Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Fmr LLC cut its stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 36.8% in the third quarter, Holdings Channel.com reports. The fund owned 8,402 shares of the biotechnology company’s stock after selling 4,884 shares during the period. Fmr LLC’s holdings in Anavex Life Sciences were worth $48,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Nwam LLC acquired a new stake in Anavex Life Sciences in the 3rd quarter valued at approximately $5,172,000. Renaissance Technologies LLC boosted its position in shares of Anavex Life Sciences by 483.8% during the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock worth $1,968,000 after buying an additional 386,537 shares during the period. Deerfield Management Company L.P. Series C acquired a new stake in shares of Anavex Life Sciences in the second quarter valued at $346,000. Squarepoint Ops LLC purchased a new stake in shares of Anavex Life Sciences in the 2nd quarter valued at $191,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Anavex Life Sciences by 17.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company’s stock valued at $1,184,000 after buying an additional 40,895 shares during the period. 31.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AVXL has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Anavex Life Sciences in a research report on Wednesday, November 27th. D. Boral Capital restated a “buy” rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a report on Monday.

Anavex Life Sciences Trading Down 2.8 %

NASDAQ:AVXL opened at $10.87 on Wednesday. Anavex Life Sciences Corp. has a 12-month low of $3.25 and a 12-month high of $12.48. The firm has a market cap of $921.73 million, a PE ratio of -21.74 and a beta of 0.73. The stock has a fifty day moving average price of $7.91 and a 200 day moving average price of $6.29.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. Equities analysts forecast that Anavex Life Sciences Corp. will post -0.55 EPS for the current year.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.